Pfizer is supporting global initiatives deploying artificial intelligence (AI) to enhance early identification of transthyretin cardiac amyloidosis (ATTR-CM), a rare and underdiagnosed cause of heart failure. Using algorithms analyzing electronic health records, ECG, and echocardiography data, the programs aim to flag at-risk patients earlier for timely diagnosis and management. These collaborations underline the increasing role of AI in improving detection rates of rare diseases, facilitating better patient outcomes through earlier interventions.